Acarix's CADScor Attracts Chinese Investment
Executive Summary
Scandinavian device maker Acarix has gained Chinese investment to boost production of its CE-marked CADScorSystem ahead of a commercial launch in 2017. The company will also form a joint venture in China.
You may also be interested in...
Acarix's Handheld CAD Device Proves Its Mettle As Frontline Test
The latest clinical data on Acarix's handheld acoustic device, the CADScor system, backs the use of the technology as a frontline test for ruling out coronary artery disease in patients presenting with suspicious chest pain. Results from a multi-center trial showed CADScor achieved a 97% negative predictive value.
AngloNordic 2015 hot picks: Unguis, RSP and Acarix
This year’s AngloNordic Medtech conference saw a raft of new companies looking for funding. Clinica picks its highlights from the meeting, held in London on 23 April
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.